| Literature DB >> 27384771 |
Berta Rodríguez-Frutos1, Laura Otero-Ortega1, María Gutiérrez-Fernández2, Blanca Fuentes1, Jaime Ramos-Cejudo1, Exuperio Díez-Tejedor3.
Abstract
Cell-based therapy has demonstrated safety and efficacy in experimental animal models of stroke, as well as safety in stroke patients. However, various questions remain regarding the therapeutic window, dosage, route of administration, and the most appropriate cell type and source, as well as mechanisms of action and immune-modulation to optimize treatment based on stem cell therapy. Various delivery routes have been used in experimental stroke models, including intracerebral, intraventricular, subarachnoid, intra-arterial, intraperitoneal, intravenous, and intranasal routes. From a clinical point of view, it is necessary to demonstrate which is the most feasible, safest, and most effective for use with stroke patients. Therefore, further experimental studies concerning the safety, efficacy, and mechanisms of action involved in these therapeutic effects are required to determine their optimal clinical use.Entities:
Keywords: Administration routes; Stem cell therapy; Stroke; Translational research
Mesh:
Year: 2016 PMID: 27384771 DOI: 10.1007/s12975-016-0482-6
Source DB: PubMed Journal: Transl Stroke Res ISSN: 1868-4483 Impact factor: 6.829